Author’s response to reviews

Title: Intronic polymorphisms in genes LRFN2 (rs2494938) and DNAH11 (rs2285947) are prognostic indicators of esophageal squamous cell carcinoma

Authors:

Jiru Wang (wjr350419@163.com)
Qiuzi Wang (314742918@qq.com)
Bin Wei (wb_934@163.com)
Yu Zhou (309556923@qq.com)
Zhaoye Qian (75530020@qq.com)
Yong Gao (hayy_gy@163.com)
Xiaofei Chen (hayycxf@163.com)

Version: 2 Date: 08 Mar 2019

Author’s response to reviews:

Dear Editors,

(RE: MGTC-D-19-00001)

We would like to thank you very much for giving us the opportunity to revise our manuscript. We also appreciate editors and reviewers for their positive and constructive comments on our manuscript. We have studied the comments carefully and taken those comments into consideration in preparing our revision. The main corrections are in the manuscript and the responds to the reviewers’ comments are as follows.

Comments of editors

Comment 1: Suggest to revise the title to:

"Intronic polymorphisms in genes LRFN2 (rs2494938) and DNAH11 (rs2285947) are associated with the prognosis in esophageal squamous cell carcinoma". or alike to mention gene name. As you didn't mention these 2 SNPs are functional, "Functional" has to be removed from the title. I
don't see rs2494938 as functional SNP as in ref 14 or in your discussion; rs2285947 may be associated with gene expression of DNAH11, per ref 14. which you can add to the discussion.

Response: We have revised the title of our manuscript to “Intronic polymorphisms in genes LRFN2 (rs2494938) and DNAH11 (rs2285947) are associated with the prognosis in esophageal squamous cell carcinoma” after our careful consideration under your constructive advice. And in the part of discussion, we added the point of the potential correlation between rs2285947 and the gene DNAH11.

Comment 2: Mention 3 gene symbols in the abstract.

Italicize gene symbol LRFN2 and DNAH11 across the manuscript (also in title), but not for protein.

Response: We have labeled the gene symbol LRFN2 and DNAH11 across the manuscript, including in the title, abstract, background and discussion.

We would like to express our great appreciation to you and reviewers for your hard work again. We’ll look forward to hearing from you soon. Thank you and best regards.

Yours sincerely,

Yong Gao, M.D.
Corresponding Author

Chief Physician
Department of Medicine Oncology
Huai'an First People's Hospital
Nanjing Medical University
Phone: 86-517-84922412, 86-13852388860
E-mail: hayy_gy@163.com